Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
出版年份 2021 全文链接
标题
Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
作者
关键词
Biomarker, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, Anti-TNF therapy
出版物
EBioMedicine
Volume 66, Issue -, Pages 103329
出版商
Elsevier BV
发表日期
2021-04-15
DOI
10.1016/j.ebiom.2021.103329
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease
- (2021) Fang Liu et al. Frontiers in Medicine
- Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn’s disease in Japan
- (2020) Hisashi Shiga et al. Scientific Reports
- Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies
- (2020) Lorenzo Bertani et al. Clinical and Translational Gastroenterology
- The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases
- (2020) Nikolas Dovrolis et al. Microorganisms
- Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
- (2020) S. Vatn et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
- (2020) Nastya Kharlamova et al. Frontiers in Immunology
- Serum Biomarkers for Inflammatory Bowel Disease
- (2020) Peng Chen et al. Frontiers in Medicine
- Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis
- (2020) Jon R. Florholmen et al. BMC GASTROENTEROLOGY
- Biomarkers of inflammation in Inflammatory Bowel Disease: how long before abandoning single-marker approaches?
- (2020) Gabriele Dragoni et al. DIGESTIVE DISEASES
- Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease
- (2020) Suruchi K Batra et al. INFLAMMATORY BOWEL DISEASES
- Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota
- (2020) Clio P Mavragani et al. INFLAMMATORY BOWEL DISEASES
- Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
- (2020) Raja Atreya et al. Frontiers in Medicine
- Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
- (2019) Bram Verstockt et al. EBioMedicine
- Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease
- (2019) Ming-Hsi Wang et al. Journal of Crohns & Colitis
- P008 Proteomic markers of response to anti-TNF drugs in patients with Crohn's disease
- (2019) R Medina-Medina et al. Journal of Crohns & Colitis
- Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease
- (2019) Steffen Bank et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
- (2019) Martine A. Aardoom et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease
- (2019) Lyssia Belarif et al. JOURNAL OF CLINICAL INVESTIGATION
- Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis
- (2019) Gole et al. Cells
- Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases
- (2019) Konrad Aden et al. GASTROENTEROLOGY
- Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review
- (2019) Maria Manuela Estevinho et al. Clinical Gastroenterology and Hepatology
- Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)
- (2019) Sare Verstockt et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN’S DISEASE BASED ON SERUM LEVELS OF PROTEINS
- (2019) Geert D’Haens et al. GASTROENTEROLOGY
- Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
- (2019) Javier P Gisbert et al. Journal of Crohns & Colitis
- TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer
- (2019) Guanglin Cui Frontiers in Oncology
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
- (2018) A. Barré et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis
- (2018) Shannon E. Telesco et al. GASTROENTEROLOGY
- Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
- (2018) Renaud Gaujoux et al. GUT
- TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn’s disease patients?
- (2018) Bram Verstockt et al. GUT
- Predicting response after infliximab salvage in acute severe ulcerative colitis
- (2018) Matthew C Choy et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients
- (2018) Matthew K. Doherty et al. mBio
- Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing
- (2018) Bram Verstockt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn’s Disease
- (2018) Belén Beltrán et al. DIGESTIVE DISEASES
- From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting
- (2018) Maria Gloria Mumolo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci
- (2018) Kimi Drobin et al. INFLAMMATORY BOWEL DISEASES
- Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response
- (2018) Yael Haberman et al. Nature Communications
- Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial
- (2017) Thomas Van Stappen et al. GUT
- Can We Predict the Efficacy of Anti-TNF-α Agents?
- (2017) Loris Lopetuso et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
- (2017) Jean-Frederic Colombel et al. LANCET
- A role for oncostatin M in inflammatory bowel disease
- (2017) Walter M Kim et al. NATURE MEDICINE
- Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
- (2017) Vendel Kristensen et al. Gastroenterology Research and Practice
- Omics Approaches to Identify Potential Biomarkers of Inflammatory Diseases in the Focal Adhesion Complex
- (2017) Johanne Brooks et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Review article: the practical management of acute severe ulcerative colitis
- (2016) D. Seah et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases
- (2016) S. Bek et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis
- (2016) Trine Olsen et al. CYTOKINE
- Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
- (2016) Amanda E Starr et al. GUT
- Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohnʼs Disease
- (2016) Frauke Degenhardt et al. INFLAMMATORY BOWEL DISEASES
- Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition
- (2016) Maria K. Magnusson et al. Journal of Crohns & Colitis
- Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
- (2016) Iris Detrez et al. Journal of Crohns & Colitis
- Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease
- (2016) Clare Moore et al. Journal of Crohns & Colitis
- Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn's Disease and Intestinal Tuberculosis
- (2016) Fenming Zhang et al. PLoS One
- Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease
- (2016) Giorgia Bodini et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population
- (2016) Jerzy Ostrowski et al. Scientific Reports
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment
- (2015) Johannan F. Brandse et al. Journal of Crohns & Colitis
- Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease
- (2015) X. Roblin et al. Journal of Crohns & Colitis
- Epidemiology and risk factors for IBD
- (2015) Ashwin N. Ananthakrishnan Nature Reviews Gastroenterology & Hepatology
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
- (2014) Niels Vande Casteele et al. GUT
- Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD
- (2014) Madeline Therese Frederiksen et al. INFLAMMATORY BOWEL DISEASES
- Molecular pathways controlling barrier function in IBD
- (2014) Raja Atreya et al. Nature Reviews Gastroenterology & Hepatology
- Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies
- (2014) Florian Beigel et al. PLoS One
- Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
- (2014) Éva Pallagi-Kunstár WORLD JOURNAL OF GASTROENTEROLOGY
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
- (2013) Fernando Magro et al. Journal of Crohns & Colitis
- Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease
- (2013) Renathe Rismo et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
- (2012) W. Reinisch et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
- (2012) Pauliina Molander et al. INFLAMMATORY BOWEL DISEASES
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- The effect of adalimumab for induction of endoscopic healing and normalization of mucosal cytokine gene expression in Crohn's disease
- (2012) Renathe Rismo et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis
- (2012) Renathe Rismo et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab†
- (2010) Zhe Li et al. INFLAMMATORY BOWEL DISEASES
- Infliximab therapy decreases the levels of TNF-α and IFN-γ mRNA in colonic mucosa of ulcerative colitis
- (2009) Trine Olsen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Proteomics for prediction and characterization of response to infliximab in Crohn's disease: A pilot study
- (2008) Marie-Alice Meuwis et al. CLINICAL BIOCHEMISTRY
- Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohnʼs disease
- (2008) Taina Sipponen et al. INFLAMMATORY BOWEL DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started